why should we target runx1 in aml treatment?
Published 5 years ago • 1.2K plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
3:18
the molecular impact of runx1 mutations in aml
-
2:02
are there germline runx1 mutations which predispose to aml?
-
1:13
dr. melnick on targeting runx1 in leukemia
-
5:41
how does targeted therapy impact aml remission?
-
2:07
what is meant by “targeted therapy” for aml?
-
3:17
are germline runx1 mutations different to somatic runx1 mutations?
-
1:48
how should family members with familial runx1 germline mutations be monitored?
-
12:11
understanding acute myeloid leukemia with runx1::runx1t1 fusion: a comprehensive guide
-
3:48
the impact of various chromosomal abnormalities observed in aml & insights into runx1-eto
-
29:07
newly diagnosed aml: hitting the right target
-
1:48
the challenges of choosing the right target antigen in aml compared to all
-
2:15
transcription factor alterations in aml and risk: runx, cepba & evi1
-
4:23
how would you treat newly diagnosed induction-eligible patients with acute myeloid leukemia?
-
1:27
how do targeted treatments for idh1 and idh2 mutations work in acute myeloid leukemia (aml)?
-
1:16
developing an understanding of disease progression in mds and aml
-
1:27
how can genetic studies inform the treatment of aml?
-
2:21
different mutant runx1 oncoproteins program
-
17:53
biology of aml developing from mds vs. de novo aml, and new targets for therapy